1-155904470-C-G
Variant summary
Our verdict is Pathogenic. Variant got 23 ACMG points: 23P and 0B. PS1_Very_StrongPM1PM2PM5PP3PP5_Very_Strong
The NM_006912.6(RIT1):c.270G>C(p.Met90Ile) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Pathogenicin ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. M90V) has been classified as Pathogenic.
Frequency
Consequence
NM_006912.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 23 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RIT1 | NM_006912.6 | c.270G>C | p.Met90Ile | missense_variant | 5/6 | ENST00000368323.8 | NP_008843.1 | |
RIT1 | NM_001256821.2 | c.321G>C | p.Met107Ile | missense_variant | 5/6 | NP_001243750.1 | ||
RIT1 | NM_001256820.2 | c.162G>C | p.Met54Ile | missense_variant | 4/5 | NP_001243749.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RIT1 | ENST00000368323.8 | c.270G>C | p.Met90Ile | missense_variant | 5/6 | 1 | NM_006912.6 | ENSP00000357306.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Noonan syndrome 8 Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | May 25, 2020 | Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as Pathogenic. Following criteria are met: 0101 - Gain-of-function is a known mechanism of disease for this gene. (N) 0107 - This gene is known to be associated with autosomal dominant disease. (N) 0200 - Variant is predicted to result in a missense amino acid change from methionine to isoleucine (exon 5). (N) 0251 - Variant is heterozygous. (N) 0301 - Variant is absent from gnomAD. (P) 0502 - Missense variant with conflicting in silico predictions and/or uninformative conservation. (N) 0601 - Variant affects at least one well established (essential) functional domain or motif. The Switch II domain is involved in GTP hydrolysis (PMID: 24469055), and missense variants cluster within this domain (ClinVar, Decipher). (P) 0801 - Strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported as pathogenic in multiple patients with Noonan syndrome, as have alternate nucleotide changes resulting in the same missense substitution (ClinVar, Mastermind). (P) 1102 - Strong phenotype match. (P) 1208 - Segregation information for this variant is not currently available. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) – Benign - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 22, 2022 | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects RIT1 function (PMID: 25959749). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (Invitae) indicates that this missense variant is expected to disrupt RIT1 function. ClinVar contains an entry for this variant (Variation ID: 190305). This missense change has been observed in individual(s) with Noonan syndrome (PMID: 23791108, 24939608, 25959749, 27101134, 27109146). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces methionine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 90 of the RIT1 protein (p.Met90Ile). - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 01, 2014 | - - |
Pathogenic, no assertion criteria provided | research | Beijing Key Laboratory for Genetic Research of Skeletal Deformity, Peking Union Medical College Hospital | May 31, 2019 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 15, 2022 | Published functional studies demonstrate increased MEK-ERK signaling compared to wild-type (Koenighofer et al., 2016); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 24939608, 24803665, 25959749, 30732632, 34006472, 35118825, 33726816, 33686258) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics and Genomics, Karolinska University Hospital | Jul 03, 2015 | - - |
RIT1-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 21, 2023 | The RIT1 c.321G>C variant is predicted to result in the amino acid substitution p.Met107Ile. In the literature this variant is also referred to as c.270G>C (p.Met90Ile) via NM_006912. This variant has been reported to be de novo in individuals with Noonan syndrome (Gos et al. 2014. PubMed ID: 24939608; Koenighofer et al. 2015. PubMed ID: 25959749; Chen et al. 2019. PubMed ID: 30732632; Frisk et al. 2022. PubMed ID: 35118825). This variant was also reported to be de novo in a fetus undergoing testing for nonimmune hydrops fetalis (Al-Kouatly et al. 2021. PubMed ID: 33686258) and in another individual undergoing testing for short stature (Table S3, Fan et al. 2021. PubMed ID: 34006472). Functional studies have shown this variant alters protein function (Koenighofer et al, 2015. PubMed ID: 25959749; Yaoita et al. 2016. PubMed ID: 26714497; Castel et al. 2019. PubMed ID: 30872527). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare, and is reported as pathogenic/likely pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/190305/). This variant is interpreted as pathogenic. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 02, 2022 | The c.270G>C (p.M90I) alteration is located in exon 5 (coding exon 4) of the RIT1 gene. This alteration results from a G to C substitution at nucleotide position 270, causing the methionine (M) at amino acid position 90 to be replaced by an isoleucine (I). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been detected in multiple individuals with clinical features of RASopathy; it has been reported to have occurred de novo in some individuals (Gos, 2014; Koenighofer, 2015; Yaoita, 2016; Chen, 2019). The same amino acid substitution resulting from c.270G>T has also been observed in individuals with RASopathy (Aoki, 2016; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In vitro functional studies showed that M90I enhances RAS-MAPK signaling (Yaoita, 2016; Koenighofer, 2015; Castel, 2019). In addition, a mouse model harboring M90I had a phenotype resembling Noonan syndrome in humans (Castel, 2019). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. - |
Noonan syndrome and Noonan-related syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Dec 12, 2016 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at